-+ 0.00%
-+ 0.00%
-+ 0.00%

Gelteq starts veterinary clinical trial for antiparasitic drug candidate under FDA pathway

PUBT·05/20/2026 12:03:02
Listen to the news
Gelteq starts veterinary clinical trial for antiparasitic drug candidate under FDA pathway
  • Gelteq started its first veterinary clinical trial for an antiparasitic drug candidate using its Gelteq technology.
  • Results have not been presented; the study is intended to generate data for a planned FDA animal-use regulatory submission later in 2026.
  • The trial is designed to support the product’s safety and performance case, positioning the program for a potential entry into the veterinary pharmaceutical market.
  • The company framed the move as part of a dual-track strategy that pairs longer-term drug development with near-term revenue from its nutraceutical business.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gelteq Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200800PRIMZONEFULLFEED9723717) on May 20, 2026, and is solely responsible for the information contained therein.